Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Robertson

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Journal of Medicinal Chemistry|December 13, 2007
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemiaJeffrey A Pfefferkorn, Chulho Choi, Scott D Larsen, et al.
Elife|November 17, 2020
Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertensionLouJin Song, Xian Chen, Terri A Swanson, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2007
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitorsWilliam K C Park, Robert M Kennedy, Scott D Larsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 29, 2021
Tumor Sink Effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?Andrei Gafita, Hui Wang, Andrew Robertson, et al.
Vaccine|October 20, 2006
Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of ageClemente Diaz, Pietro Dentico, Rocio Gonzalez, et al.
The Lancet. Oncology|July 11, 2021
Nomograms to predict outcomes after <sup>177</sup>Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective studyAndrei Gafita, Jeremie Calais, Tristan R Grogan, et al.
Journal of Gastroenterology and Hepatology|December 31, 2020
Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohortNikolas Plevris, James Fulforth, Spyros Siakavellas, et al.
Nature Microbiology|April 2, 2022
Mechanistic insights into consumption of the food additive xanthan gum by the human gut microbiotaMatthew P Ostrowski, Sabina Leanti La Rosa, Benoit J Kunath, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2007
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitorsJeffrey A Pfefferkorn, Yuntao Song, Kuai-Lin Sun, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2010
Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distributionJeffrey A Pfefferkorn, John Litchfield, Richard Hutchings, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Journal of Medicinal Chemistry|December 13, 2007
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemiaJeffrey A Pfefferkorn, Chulho Choi, Scott D Larsen, et al.
Elife|November 17, 2020
Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertensionLouJin Song, Xian Chen, Terri A Swanson, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2007
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitorsWilliam K C Park, Robert M Kennedy, Scott D Larsen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 29, 2021
Tumor Sink Effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?Andrei Gafita, Hui Wang, Andrew Robertson, et al.
Vaccine|October 20, 2006
Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of ageClemente Diaz, Pietro Dentico, Rocio Gonzalez, et al.
The Lancet. Oncology|July 11, 2021
Nomograms to predict outcomes after <sup>177</sup>Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective studyAndrei Gafita, Jeremie Calais, Tristan R Grogan, et al.
Journal of Gastroenterology and Hepatology|December 31, 2020
Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohortNikolas Plevris, James Fulforth, Spyros Siakavellas, et al.
Nature Microbiology|April 2, 2022
Mechanistic insights into consumption of the food additive xanthan gum by the human gut microbiotaMatthew P Ostrowski, Sabina Leanti La Rosa, Benoit J Kunath, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2007
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitorsJeffrey A Pfefferkorn, Yuntao Song, Kuai-Lin Sun, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2010
Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distributionJeffrey A Pfefferkorn, John Litchfield, Richard Hutchings, et al.
Pageof 9